

Pillar 3 Regulatory Disclosures

For the quarterly period ended March 31, 2020

March 31, 2020 Pillar 3 Regulatory Disclosures

TABLE OF CONTENTS

| Glossary of Acronyms and Terms | 2 |
|--|----|
| Introduction | 4 |
| Report Overview | 4 |
| Scope of Application | 4 |
| Risk Governance | 5 |
| Capital Structure and Adequacy | 6 |
| Capital Structure | 8 |
| Credit Risk | 11 |
| Credit Risk Exposure Counterparty Credit Risk-Related Disclosures Credit Risk Mitigation | 15 |
| Securitization | 17 |
| Equities (Non-Trading) | 18 |
| Market Risk | 19 |
| Appendix 1 - Citizens Financial Group, Inc. Pillar 3 Regulatory Disclosures Matrix | 20 |
| Appendix 2 - Forward-Looking Statements | 23 |

March 31, 2020 Pillar 3 Regulatory Disclosures

GLOSSARY OF ACRONYMS AND TERMS

The following is a list of common acronyms and terms we regularly use in our financial reporting:

| AACL | Adjusted Allowance for Credit Losses |
|--|--|
| ACL | Allowance for Credit Losses: Allowance for Loan and Lease Losses plus Reserve for Unfunded Lending Commitments |
| AFS | Available for Sale |
| AOCI | Accumulated Other Comprehensive Income (Loss) |
| ВНС | Bank Holding Company |
| Board | The Board of Directors of Citizens Financial Group, Inc. |
| CBNA | Citizens Bank, National Association |
| CCAR | Comprehensive Capital Analysis and Review |
| ССВ | Capital Conservation Buffer |
| CECL | Current Expected Credit Losses (ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments) |
| CET1 | Common Equity Tier 1 |
| CET1 capital ratio | Common Equity Tier 1 capital divided by total risk-weighted assets as defined under the U.S. Basel III Standardized approach |
| СГРВ | Consumer Financial Protection Bureau |
| Citizens, CFG, the Company, we, us, or our | Citizens Financial Group, Inc. and its Subsidiaries |
| CRA | Community Reinvestment Act |
| CSA | Credit Support Annex |
| CVA | Credit Valuation Adjustment |
| Dodd-Frank Act | The Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 |
| EGRRCPA | Economic Growth, Regulatory Relief, and Consumer Protection Act |
| FDIA | Federal Deposit Insurance Act |
| FHLB | Federal Home Loan Bank |
| FHLMC | Federal Home Loan Mortgage Corporation |
| FNMA | Federal National Mortgage Association |
| Form 10-K | Annual Report on Form 10-K |
| Form 10-Q | Quarterly Report on Form 10-Q |
| FR Y-9C | Regulatory Financial Statements for Bank Holding Companies |
| FRB or Federal Reserve | Board of Governors of the Federal Reserve System and, as applicable, Federal Reserve Bank(s) |
| GAAP | Accounting Principles Generally Accepted in the United States of America |
| GNMA | Government National Mortgage Association |
| MBS | Mortgage-Backed Securities |
| Mid-Atlantic | District of Columbia, Delaware, Maryland, New Jersey, New York, Pennsylvania, Virginia, and West Virginia |
| Midwest | Illinois, Indiana, Michigan, and Ohio |
| Modified AACL Transition | The Day-1 CECL adoption entry booked to ACL plus 25% of subsequent CECL ACL reserve build |
| Modified CECL Transition | The Day-1 CECL adoption entry booked to retained earnings plus 25% of subsequent CECL ACL reserve build |
| New England | Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont |
| NRSRO | Nationally Recognized Statistical Ratings Organizations |

March 31, 2020 Pillar 3 Regulatory Disclosures

| OCC | Office of the Comptroller of the Currency |
|-----------------------|---|
| отс | Over the Counter |
| Parent Company | Citizens Financial Group, Inc. (the Parent Company of Citizens Bank, National Association and other subsidiaries) |
| RWA | Risk-Weighted Assets |
| SSFA | Simplified Supervisory Formula Approach |
| Tier 1 capital ratio | Tier 1 capital, which includes Common Equity Tier 1 capital plus non-cumulative perpetual preferred equity that qualifies as additional tier 1 capital, divided by total risk-weighted assets as defined under the U.S. Basel III Standardized approach |
| Tier 1 leverage ratio | Tier 1 capital, which includes Common Equity Tier 1 capital plus non-cumulative perpetual preferred equity that qualifies as additional tier 1 capital, divided by quarterly adjusted average assets as defined under the U.S. Basel III Standardized approach |
| Total capital ratio | Total capital, which includes Common Equity Tier 1 capital, tier 1 capital and allowance for credit losses and qualifying subordinated debt that qualifies as tier 2 capital, divided by total risk-weighted assets as defined under the U.S. Basel III Standardized approach |
| VaR | Value at Risk |

March 31, 2020 Pillar 3 Regulatory Disclosures

INTRODUCTION

Citizens Financial Group, Inc. is one of the nation's oldest and largest financial institutions with \$176.7 billion in assets as of March 31, 2020. Our mission is to help customers, colleagues and communities each reach their potential by listening to them and understanding their needs in order to offer tailored advice, ideas and solutions. Headquartered in Providence, Rhode Island, we offer a broad range of retail and commercial banking products and services to individuals, small businesses, middle-market companies, large corporations and institutions. In Consumer Banking, we provide an integrated experience that includes mobile and online banking, a 24/7 customer contact center as well as the convenience of approximately 2,800 ATMs and 1,000 branches in 11 states in the New England, Mid-Atlantic, and Midwest regions. Consumer Banking products and services include a full range of banking, lending, savings, wealth management and small business offerings. In Commercial Banking, we offer corporate, institutional and not-for-profit clients a full range of wholesale banking products and services including lending and deposits, capital markets, treasury services, foreign exchange and interest rate products, and asset finance. More information is available at www.citizensbank.com.

Report Overview

We produce this report quarterly to update market participants regarding risk-based capital and risk exposures as required under U.S. regulations that interpret global regulatory standards known as "Basel III." The U.S. banking regulators refer to this ongoing requirement as "Pillar 3 Regulatory Disclosures." This report provides information on our capital structure, risk exposures, risk assessment processes, RWA and overall capital adequacy. This report also includes information on the methodologies used to calculate RWA. This report is unaudited and should be read in conjunction with our 2019 Form 10-K and Form 10-Q for the period ended March 31, 2020, which include important information on risk management policies and practices, and our March 31, 2020 FR Y-9C. Appendix 1 of this report contains references to specific sections of our 2019 Form 10-K and Form 10-Q for the period ended March 31, 2020 to facilitate location of applicable information.

This report may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statement that does not describe historical or current facts is a forward-looking statement, as discussed further in Appendix 2 of this report.

Scope of Application

The U.S. Basel III framework applies to CFG and its subsidiary bank, CBNA. CFG is a "standardized approach" and "AOCI opt-out" reporting institution under the U.S. Basel III Standardized approach. Our basis for consolidation used for regulatory financial statement reporting purposes is the same as the basis used for our financial statements prepared under GAAP. Please refer to Note 1 in our 2019 Form 10-K and Note 1 in our Form 10-Q for the period ended March 31, 2020 for more information on the basis for consolidation for financial reporting purposes.

Restrictions on transfers between CFG and CBNA

A number of regulations and statutes restrict transfers of funds and capital within CFG. CFG is a financial holding company and a BHC, regulated and supervised by the FRB. The OCC is the primary regulator and supervisor for CBNA. Applicable statutes and regulations that may pertain either to CFG, CBNA, and all entities as affiliates may restrict transfers of funds and capital between these entities.

Sections 23A and 23B of the Federal Reserve Act and FRB Regulation W are the primary restrictors of lending, borrowing, and otherwise transacting business between affiliates. Please refer to "Business - Regulation and Supervision - Transactions with Affiliates and Insiders" in our 2019 Form 10-K for a discussion of these regulations.

Restrictions on the payment of dividends and other capital distributions weighs most heavily on CBNA. The FRB expects a BHC to act as a "source of strength" to each individual subsidiary bank it holds, providing capital as needed. Consistent with this view, bank regulators ensure that a bank does not return capital to the BHC in a manner that would undermine its overall "safety and soundness." Therefore, CBNA is subject to specific qualitative and quantitative tests and examinations that may restrict it from paying dividends or otherwise returning capital to the

March 31, 2020 Pillar 3 Regulatory Disclosures

Parent Company. For more information, please refer to "Business - Regulation and Supervision" in our 2019 Form 10-K for an overview of the general controls and restrictions imposed on distributions of capital by CBNA and "Management's Discussion and Analysis of Financial Condition and Results of Operations - Capital and Regulatory Matters" in our Form 10-Q for the period ended March 31, 2020 for details of CBNA's status versus its applicable regulatory minimums.

In addition, CFG and CBNA are subject to capital adequacy and liquidity standards. If CFG or CBNA fail to meet these standards, it could have an adverse effect on our financial condition and operations. Please refer to "Risk Factors - Risks Related to Regulations Governing Our Industry" in our 2019 Form 10-K and "Risk Factors" in our Form 10-Q for the period ended March 31, 2020 for additional information regarding these risks.

RISK GOVERNANCE

We are committed to maintaining a strong, integrated, and proactive approach to the management of all risks to which we are exposed in pursuit of our business objectives. A key aspect of our Board's responsibility as the main decision making body is setting our risk appetite to ensure that the levels of risk that we are willing to accept in the attainment of our strategic business and financial objectives are clearly understood.

To enable our Board to carry out its objectives, it has delegated authority for risk management activities, as well as governance and oversight of those activities, to a number of Board and executive management level risk committees. The Executive Risk Committee ("ERC"), chaired by the Chief Risk Officer, is responsible for oversight of risk across the enterprise and actively considers our inherent material risks, analyzes our overall risk profile and seeks confirmation that the risks are being appropriately identified, assessed and mitigated. Reporting to the ERC are the following additional committees covering specific areas of risk: Compliance and Operational Risk Committee, Model Risk Committee, Credit Policy Committee, Asset Liability Committee, Business Initiatives Review Committee, and the Conduct and Ethics Committee.

Please refer to "Management's Discussion and Analysis of Financial Condition and Results of Operations - Risk Governance" in our 2019 Form 10-K for additional information on our risk governance practices.

March 31, 2020 Pillar 3 Regulatory Disclosures

CAPITAL STRUCTURE AND ADEQUACY

prior to the applicable maturity date.

Capital Structure

We manage capital to ensure consistency with all applicable regulations and statutes, as well as with Board-approved internal policies established to ensure that the quantity and quality of current and projected capital will be adequate in relation to the risks that we assume across all lines of business. Please refer to "Management's Discussion and Analysis of Financial Condition and Results of Operations - Capital and Regulatory Matters" in our Form 10-Q for the period ended March 31, 2020 for additional information. As of March 31, 2020, our regulatory capital instruments consisted of common equity that qualifies as CET1 capital, preferred stock that qualifies as additional tier 1 capital, and subordinated debt that qualifies as tier 2 capital. Table 1 below presents our regulatory capital instruments.

| Table 1 | |
|---|----------------------|
| (in millions, except share and per share data) | As of March 31, 2020 |
| Common Equity | |
| Common stock and related surplus, net of treasury stock | \$14,284 |
| \$.01 par value, 1,000,000,000 shares authorized, 569,252,835 shares issued, and 426,586,533 shares outstanding | g |
| Preferred Equity | |
| Preferred stock and related surplus | |
| \$25.00 par value, 100,000,000 shares authorized, liquidation preference of \$1,000 per share: | |
| Series A: 250,000 shares issued and outstanding | 247 |
| Series B: 300,000 shares issued and outstanding | 296 |
| Series C: 300,000 shares issued and outstanding | 297 |
| Series D: 300,000 ⁽¹⁾ shares issued and outstanding | 293 |
| Series E: 450,000 ⁽²⁾ shares issued and outstanding | 437 |
| Total preferred stock and related surplus | \$1,570 |
| Qualifying Subordinated Debt | |
| 4.150% fixed-rate subordinated debt, due September 2022 (non-qualifying \$209) ⁽³⁾ | 139 |
| 3.750% fixed-rate subordinated debt, due July 2024 (non-qualifying \$50) ⁽³⁾ | 200 |
| 4.023% fixed-rate subordinated debt, due October 2024 (non-qualifying \$8) ⁽³⁾ | 34 |
| 4.350% fixed-rate subordinated debt, due August 2025 | 249 |
| 4.300% fixed-rate subordinated debt, due December 2025 | 750 |
| Total qualifying subordinated debt | \$1,372 |

⁽¹⁾ Represented by 12,000,000 depositary shares each representing a 1/40th interest and a liquidation preference of \$25 per depositary share.

Our regulatory deductions from CET1 capital include goodwill and intangible assets net of deferred tax liabilities associated with goodwill and intangible assets. The U.S. Basel III capital rules also require additional capital deductions for mortgage servicing rights ("MSRs"), certain deferred tax assets ("DTAs") and significant investments in the capital of unconsolidated financial institutions in excess of 10% individually, or 15% in aggregate, of CET1 capital less certain adjustments. As of March 31, 2020, we do not meet the threshold for these additional capital deductions.

In July 2019, the FRB and the other federal banking regulators issued a final rule to simplify regulatory capital treatment for MSRs, certain DTAs and significant investments in the capital of unconsolidated financial institutions, pursuant to EGRRCPA. Effective for us on April 1, 2020, the final rule will change the individual CET1 deduction threshold for these assets from 10% to 25%, eliminate the aggregate deduction threshold for these assets of 15%, assign a 250% risk weight for any MSRs or DTAs not deducted from CET1 capital, and assign an exposure category risk weight for investments in the capital of unconsolidated financial institutions not deducted from CET1 capital.

⁽²⁾ Represented by 18,000,000 depositary shares each representing a 1/40th interest and a liquidation preference of \$25 per depositary share.
(3) Per the U.S. Basel III Standardized rules, tier 2 capital instrument eligibility for inclusion in regulatory capital is phased out 20% per year, beginning five years

March 31, 2020 Pillar 3 Regulatory Disclosures

On January 1, 2020, we adopted the CECL accounting standard. On March 31, 2020, in response to the COVID-19 pandemic, the FRB and the other federal banking regulators issued an interim final rule relative to regulatory capital treatment of ACL under CECL. This rule allowed banking organizations to delay the estimated impact of CECL on regulatory capital for a two-year period ending January 1, 2022, followed by a three-year transition period ending January 1, 2025 to phase-in the aggregate amount of the capital benefit provided during the initial two-year delay.

As an "AOCI opt-out" institution, we are not required to recognize in regulatory capital the impacts of net unrealized gains and losses included within AOCI for debt securities that are available for sale or held to maturity, accumulated net gains and losses on cash flow hedges and certain defined benefit pension plan assets.

As of March 31, 2020, CET1 capital represented 75% of our total regulatory capital. Table 2 below presents our regulatory capital composition.

| Table 2 | | | | |
|---|----------------------|--|--|--|
| (in millions) | As of March 31, 2020 | | | |
| Common stock and related surplus, net of treasury stock | \$14,284 | | | |
| Retained earnings | 6,011 | | | |
| Accumulated other comprehensive income | 85 | | | |
| Total common shareholders' equity | 20,380 | | | |
| Exclusions: | | | | |
| Modified CECL transitional amount | 453 | | | |
| Net unrealized (gains)/losses recorded in accumulated other comprehensive income, net of tax: | | | | |
| Debt securities | (401) | | | |
| Derivatives | (96) | | | |
| Unamortized net periodic benefit costs | 412 | | | |
| <u>Deductions</u> : | | | | |
| Goodwill | (7,050) | | | |
| Deferred tax liability associated with goodwill | 375 | | | |
| Other intangible assets | (66) | | | |
| Total common equity tier 1 capital | 14,007 | | | |
| Qualifying preferred stock | 1,570 | | | |
| Total tier 1 capital | 15,577 | | | |
| Qualifying subordinated debt ⁽¹⁾ | 1,372 | | | |
| Allowance for credit losses | 2,210 | | | |
| Exclusions from tier 2 capital: | | | | |
| Modified AACL transitional amount | (567) | | | |
| Adjusted allowance for credit losses ⁽²⁾ | 1,643 | | | |
| Total tier 2 capital | 3,015 | | | |
| Total capital | \$18,592 | | | |

⁽¹⁾ Non-qualifying subordinated debt excluded from regulatory capital is \$267 million.

⁽²⁾ Excludes allowances on purchased credit-deteriorated assets and AFS debt securities.

March 31, 2020 Pillar 3 Regulatory Disclosures

Capital Adequacy Process

Our assessment of capital adequacy begins with our risk appetite and risk management framework. This framework provides for the identification, measurement and management of material risks. For more information on our capital adequacy risk appetite and risk management framework, please refer to "Management's Discussion and Analysis of Financial Condition and Results of Operations - Capital and Regulatory Matters" in our 2019 Form 10-K and "Risk Factors" in our Form 10-Q for the period ended March 31, 2020.

We develop a capital plan and conduct routine capital management activities in compliance with internal limits and operating targets that are established for each regulatory capital ratio. These limits and targets are intended to meet both regulatory and market expectations, while also ensuring an efficient return to shareholders. We set these internal limits and targets to comply with the U.S. Basel III minimums, which include the capital conservation buffer of 2.5% for each risk-weighted capital ratio. Please refer to the related discussion in the "Capital Conservation Buffer" section of this report. The process to establish internal limits and targets also considers internally defined buffers for stress uncertainty and other strategic considerations, which are calibrated annually.

In October 2019, the FRB finalized rules that establish a revised framework for applying prudential standards to large U.S. banking organizations based on risk, consistent with the ongoing efforts to tailor the regulatory framework in a manner consistent with the EGRRCPA. Concurrently, the FRB and other banking regulators finalized the regulatory capital, liquidity and resolution plan requirements to firms with more than \$100 billion in total assets. Category IV firms with \$100 billion to \$250 billion in total assets, such as us, will be subject to biennial supervisory stress-testing and will be exempt from company-run stress testing and related disclosure requirements. The FRB will continue to supervise Category IV firms on an ongoing basis, including evaluation of the capital adequacy and capital planning processes during off-cycle years.

In light of the Tailoring Rules, the FRB provided us relief in February 2019 from certain regulatory requirements related to supervisory stress testing, company-run stress testing, and related disclosure requirements for the 2019 stress test cycle. As a result, we were not required to participate in the supervisory stress test of CCAR, conduct company-run stress tests, or submit a capital plan to the FRB for 2019. We remain subject to the requirement to develop and maintain an annual capital plan that is reviewed and approved by our Board of Directors (or one of its committees), as well as FR Y-14 reporting requirements. The FRB has not objected to our maximum planned capital actions for the period beginning July 1, 2019 and ending June 30, 2020, which are largely based on the results for our 2018 supervisory stress test, adjusted for any changes in our regulatory capital ratios since the FRB acted on our 2018 capital plan. On April 17, 2020, we announced that in order to ensure capital remains strong to meet further loan demand during the COVID-19 crisis, we would cease stock repurchases through December 31, 2020. On April 6, 2020, we submitted our 2020 capital plan to the FRB.

On March 4, 2020, the FRB finalized a rule that simplifies capital rules for large banks and establishes a stress capital buffer ("SCB") requirement. The final rule integrates regulatory capital requirements with the results of the FRB's supervisory stress tests by replacing the capital conservation buffer, which is currently 2.5%, with the SCB. The SCB will be determined as the higher of either 2.5%, or the difference between the starting and the minimum projected CET1 capital ratio under the severely adverse scenario as modeled by the FRB as part of the supervisory stress testing framework. The SCB will include four quarters of planned dividends for each bank on top of the FRB-modeled losses. Under the SCB framework, the FRB will no longer object to capital plans on quantitative grounds and each firm will be required to maintain capital ratios above the sum of its minimum requirements and the SCB requirements to avoid restrictions on capital distributions and discretionary bonus payments. The SCB will be re-calibrated with each CCAR supervisory stress test (annually for Category I, II and III firms, and every other year for Category IV firms, such as us) and will be effective on October 1 of each year through September 30 of the following year. The first SCB requirement goes into effect on October 1, 2020 and will apply to our capital actions over the four-quarter period beginning October 1, 2020 through September 30, 2021. Capital actions for the transition quarter beginning July 1 through September 30, 2020 may not exceed the four-quarter average of capital distributions authorized by the FRB for the 2019 capital plan cycle.

Many of the provisions of the EGRRCPA and other laws are subject to further rulemaking, guidance and interpretation by the applicable federal regulators. The ultimate effects of EGRRCPA and the Tailoring Rules on us and our activities will be subject to any additional rule making issued by the FRB and other federal regulators. We will continue to

March 31, 2020 Pillar 3 Regulatory Disclosures

evaluate the impact of any changes in law and any new regulations promulgated, including changes in regulatory costs and fees, modifications to consumer products or disclosures required by the CFPB and the requirements of the enhanced supervision provisions, among others.

For additional discussion of the EGRRCPA and the Tailoring Rules, see "Business - Regulation and Supervision" and "Management's Discussion and Analysis of Financial Condition and Results of Operations - Capital and Regulatory Matters" in our 2019 Form 10-K.

Table 3 below presents the U.S. Basel III Standardized capital ratios for CFG and CBNA as of March 31, 2020. All ratios remained well above the U.S. Basel III minimums. Please refer to "Management's Discussion and Analysis of Financial Condition and Results of Operations - Capital and Regulatory Matters" in our Form 10-Q for the period ended March 31, 2020 for additional information related to the calculation of our capital ratios.

| Table 3 | | | | | | |
|--|--------------------------------|----------------------------|------|--|--|--|
| | Citizens Financial Group, Inc. | | | | | |
| Required Minimum plus FDIA Required Well-Capita Required CCB for Non- Minimum for Purposes of P Ratio Leverage Ratios Corrective Action ⁽¹⁾ | | | | | | |
| CET1 capital | 9.4% | 7.0% | N/A | | | |
| Tier 1 capital | 10.5 | 8.5 | N/A | | | |
| Total capital | 12.5 | 10.5 | N/A | | | |
| Tier 1 Leverage | 9.6 | 4.0 | N/A | | | |
| | Citizens | Bank, National Association | | | | |
| Required Minimum plus FDIA Required Well-Capitalized Required CCB for Non- Minimum for Purposes of Prompt Ratio Leverage Ratios Corrective Action | | | | | | |
| CET1 capital | 10.4% | 7.0% | 6.5% | | | |
| Tier 1 capital | 10.4 | 8.5 | 8.0 | | | |
| Total capital | 12.2 | 10.5 | 10.0 | | | |
| Tier 1 Leverage | 9.6 | 4.0 | 5.0 | | | |

⁽¹⁾ Prompt corrective action provisions apply only to our insured depository institution, CBNA.

March 31, 2020 Pillar 3 Regulatory Disclosures

Table 4 below presents the composition of our RWA. Please refer to "Schedule HC-R - Part II Risk-Weighted Assets" in our March 31, 2020 FR Y-9C report for details on adjustments and deductions to calculate total RWA.

| Table 4 | | | |
|--|----------------------|--|--|
| (in millions) | As of March 31, 2020 | | |
| Corporate exposures | \$77,356 | | |
| Other retail exposures | 37,203 | | |
| Other assets | 13,714 | | |
| Residential mortgage exposures | 10,902 | | |
| Mortgage backed securities - FNMA & FHLMC | 2,562 | | |
| Equities | 2,103 | | |
| Letters of credit | 1,992 | | |
| Past due loans (excluding Sovereigns, Guarantees & Home Lending) | 730 | | |
| Securitization exposures | 643 | | |
| High volatility commercial real estate | 613 | | |
| Exposures to sovereign entities | 256 | | |
| Exposures to depository institutions, foreign banks, and credit unions | 58 | | |
| Cleared transactions | 29 | | |
| Exposures to public sector entities | 10 | | |
| Default fund contributions | 1 | | |
| Total standardized risk-weighted assets for credit risk exposure | \$148,172 | | |
| Market risk | 774 | | |
| Total risk-weighted assets | \$148,946 | | |

Please refer to "Management's Discussion and Analysis of Financial Condition and Results of Operations - Capital and Regulatory Matters" in our Form 10-Q for the period ended March 31, 2020 for more information regarding capital ratios and the capital adequacy process.

Capital Conservation Buffer

The U.S. Basel III rules impose a CCB on top of the regulatory minimum established for each of the three risk-weighted asset ratios. Under the U.S. Basel III Standardized rules, the effective minimum capital ratios are:

- 7.0% CET1 capital to RWA (minimum 4.5% plus 2.5% CCB);
- 8.5% Tier 1 capital (CET1 plus Additional Tier 1 capital) to RWA (minimum 6% plus 2.5% CCB); and
- 10.5% Total capital (Tier 1 capital plus Tier 2 capital) to RWA (minimum 8% plus 2.5% CCB).

As of March 31, 2020, CFG's CCB was 4.5%, well above the U.S. Basel III Standardized CCB of 2.5%. As a result, we are not subject to payout ratio limitations on our distributions or certain discretionary executive compensation. On March 20, 2020, the FRB and the other federal banking regulators issued an interim final rule as a result of the COVID-19 pandemic relative to the definition of eligible retained income⁽¹⁾. As a result, eligible retained income at March 31, 2020 was \$448 million, consisting of the average net income over the preceding four quarters.

⁽¹⁾ Eligible retained income, effective March 31, 2020 is defined by regulations as the greater of (1) net income for the four preceding calendar quarters, net of any distributions and associated tax effects not already reflected in net income, and (2) the average of a banking organization's net income over the preceding four quarters.

March 31, 2020 Pillar 3 Regulatory Disclosures

CREDIT RISK

Credit Risk Exposure

Table 5 below presents total credit risk exposures for our loans, loans held for sale, leases, contractual commitments to extend credit, and letters of credit. This table is categorized by counterparty types (commercial and retail) and loan products. Beginning in the first quarter of 2020, home equity loans, home equity lines of credit, home equity loans serviced by others and home equity lines of credit serviced by others were consolidated into home equity, and credit card and other retail were consolidated into other retail.

Please refer to "Management's Discussion and Analysis of Financial Condition and Results of Operations - Risk Governance - Credit Risk" in our 2019 Form 10-K for more information on credit risk governance.

| Table 5 | | |
|------------------------|----------------------|--|
| (in millions) | As of March 31, 2020 | |
| Commercial | \$79,519 | |
| Commercial real estate | 22,166 | |
| Leases | 2,685 | |
| Total commercial | 104,370 | |
| Residential mortgages | 22,922 | |
| Home equity | 29,138 | |
| Automobile | 12,157 | |
| Education | 11,011 | |
| Other retail | 18,082 | |
| Total retail | 93,310 | |
| Total | \$197,680 | |

Our loan and lease credit related accounting policies are presented in Note 5 in our 2019 Form 10-K and Note 4 in our Form 10-Q for the period ended March 31, 2020.

Our investment securities portfolio includes U.S. Treasury and agency securities, agency mortgage-backed securities, and non-agency mortgage-backed securities. The most important element management relies on when assessing credit risk for U.S. Treasury and agency securities and agency mortgage-backed securities is the guarantee of the Federal Government or one of its agencies. When applicable, we consider geography as a factor when managing our investments in securities issued by state and political subdivisions. The credit risk for non-agency mortgage-backed securities is assessed based on senior to subordinated credit support levels and an analysis of the bond's underlying collateral characteristics. As a secondary measure, ratings by NRSRO are considered, but not solely relied upon, to determine the creditworthiness of the issuance.

Please refer to Note 2 and Note 9 in our Form 10-Q for the period ended March 31, 2020 and the "Counterparty Credit Risk-Related Disclosures" section of this report for more information on our credit risk exposures related to investment securities and derivatives. Please refer to "Management's Discussion and Analysis of Financial Condition and Results of Operations - Net Interest Income" in our Form 10-Q for the period ended March 31, 2020 for average balances of our loans and leases and investment securities. The average credit risk exposure related to our OTC derivatives for the quarter ended March 31, 2020 was \$1.3 billion.

Please refer to Note 12 in our Form 10-Q for the period ended March 31, 2020 for more information on the credit risk exposure related to our off-balance sheet commitments (including contractual commitments to extend credit and letters of credit). The average credit risk exposure associated with our off-balance sheet credit commitments and letters of credit for the quarter ended March 31, 2020 was \$71 billion.

March 31, 2020 Pillar 3 Regulatory Disclosures

Table 6 below presents the geographic distribution of our loans, loans held for sale, leases, credit commitments and letters of credit. The geographic distribution presented in this table uses the address of the customer as the basis for classification. Amounts reported as "Other" include credit to customers outside of the Mid-Atlantic, Midwest, and New England regions, as well as certain exposures that we do not manage on a geographic basis, such as merchant point-of-sale financing.

| Table 6 | | | | | |
|------------------------|----------------------|----------|-------------|----------|-----------|
| | As of March 31, 2020 | | | | |
| (in millions) | Mid-Atlantic | Midwest | New England | Other | Total |
| Commercial | \$27,881 | \$9,630 | \$17,690 | \$24,318 | \$79,519 |
| Commercial real estate | 6,687 | 2,198 | 2,724 | 10,557 | 22,166 |
| Leases | 671 | 488 | 192 | 1,334 | 2,685 |
| Total commercial | 35,239 | 12,316 | 20,606 | 36,209 | 104,370 |
| Residential mortgages | 11,212 | 1,476 | 4,496 | 5,738 | 22,922 |
| Home equity | 12,071 | 3,263 | 12,983 | 821 | 29,138 |
| Automobile | 3,693 | 1,932 | 1,708 | 4,824 | 12,157 |
| Education | 4,067 | 1,443 | 2,112 | 3,389 | 11,011 |
| Other retail | 5,626 | 2,128 | 4,718 | 5,610 | 18,082 |
| Total retail | 36,669 | 10,242 | 26,017 | 20,382 | 93,310 |
| Total | \$71,908 | \$22,558 | \$46,623 | \$56,591 | \$197,680 |

Our gross commercial and retail charge-offs for the quarter-to-date period ended March 31, 2020 were \$47 million and \$127 million, respectively. Upon adoption of CECL effective January 1, 2020, our ACL reserve methodology changed to estimate expected credit losses over the contractual life of the loans and leases. The ACL reserve is measured based on groups of loans with similar risk characteristics and is not disaggregated on the basis of impairment method.

The following table presents our AACL balance at the end of the period. Please refer to Note 4 in our Form 10-Q for the period ended March 31, 2020 for more information on ACL including ACL balances and related year-to-date charge-off information.

| Table 7 | |
|---|----------------------|
| (in millions) | As of March 31, 2020 |
| ACL | \$2,210 |
| Less: modified AACL transitional amount | (567) |
| Less: credit loss allowance on AFS debt securities | _ |
| Less: credit loss allowance on purchased credit-deteriorated assets | _ |
| AACL | \$1,643 |

March 31, 2020 Pillar 3 Regulatory Disclosures

Table 8 below presents our loans and leases past due 90 days and on nonaccrual and loans past due 90 days and still accruing.

| Table 8 | | | | | |
|-----------------------------------|---------------------------------------|-----------------------------------|----------------------------|--|--|
| | As of March 31, 2020 | | | | |
| (in millions) | 90+ Days Past Due and Accruing (1) | 90+ Days Past Due and Nonaccruing | Total 90+ Days Past Due | | |
| Commercial | \$- | \$58 | \$58 | | |
| Commercial real estate | _ | 1 | 1 | | |
| Leases | _ | 1 | 1 | | |
| Total commercial loans and leases | _ | 60 | 60 | | |
| Residential mortgages | 14 | 80 | 94 | | |
| Home equity | _ | 185 | 185 | | |
| Automobile | _ | 23 | 23 | | |
| Education | 2 | 13 | 15 | | |
| Other retail | 11 | 31 | 42 | | |
| Total retail loans | 27 | 332 | 359 | | |
| Total | \$27 | \$392 | \$419 | | |

 $^{^{(1)}}$ For residential mortgages, includes \$13 million of first lien residential mortgages that are 100% guaranteed by the Federal Housing Administration.

Table 9 below presents our impaired loan amounts categorized by geographic area. Impaired loans include nonaccruing larger balance commercial loans (greater than \$5 million carrying value), non-homogeneous commercial and commercial real estate loans, and restructured loans that are deemed troubled debt restructurings.

| Table 9 | | | | | |
|------------------------|----------------------|---------|-------------|-------|---------|
| | As of March 31, 2020 | | | | |
| (in millions) | Mid-Atlantic | Midwest | New England | Other | Total |
| Commercial | \$170 | \$7 | \$153 | \$92 | \$422 |
| Commercial real estate | 24 | _ | _ | _ | 24 |
| Total commercial loans | 194 | 7 | 153 | 92 | 446 |
| Residential mortgages | 64 | 26 | 33 | 44 | 167 |
| Home equity | 106 | 71 | 118 | 23 | 318 |
| Automobile | 5 | 3 | 2 | 5 | 15 |
| Education | - | _ | _ | 131 | 131 |
| Other retail | 11 | 4 | 9 | 9 | 33 |
| Total retail loans | 186 | 104 | 162 | 212 | 664 |
| Total | \$380 | \$111 | \$315 | \$304 | \$1,110 |

March 31, 2020 Pillar 3 Regulatory Disclosures

The following table presents a summary of impaired loans with and without a related allowance:

| Table 10 | | | | | | |
|------------------------|---|--|---|--|--|--|
| | As of Marc | As of March 31, 2020 | | | | |
| (in millions) | Impaired Loans With a Related Allowance | Impaired Loans Without a Related Allowance | Total Recorded Investment in Impaired Loans | | | |
| Commercial | \$322 | \$322 \$100 | | | | |
| Commercial real estate | _ | _ 24 | | | | |
| Total commercial loans | 322 | 124 | 446 | | | |
| Residential mortgages | 46 | 121 | 167 | | | |
| Home equity | 69 | 249 | 318 | | | |
| Automobile | _ | 15 | 15 | | | |
| Education | 109 | 22 | 131 | | | |
| Other retail | 30 | 30 3 | | | | |
| Total retail loans | 254 | 410 | 664 | | | |
| Total | \$576 | \$534 | \$1,110 | | | |

Table 11 below presents a summary of our loans, loans held for sale and leases by remaining maturity or repricing date.

| | Table 11 | | | |
|-----------------------------------|------------------------------------|--|-----------------|-----------|
| | As of March 31, 2020 | | | |
| (in millions) | One Year or Less ⁽¹⁾ | Over One Year Through Five Years | Over Five Years | Total |
| Commercial | \$45,328 | \$2,727 | \$1,590 | \$49,645 |
| Commercial real estate | 14,150 | 130 | 222 | 14,502 |
| Leases | 555 | 1,539 | 344 | 2,438 |
| Total commercial loans and leases | 60,033 | 4,396 | 2,156 | 66,585 |
| Residential mortgages | 3,667 | 2,462 | 15,300 | 21,429 |
| Home equity | 11,851 | 460 | 681 | 12,992 |
| Automobile | 195 | 6,906 | 5,056 | 12,157 |
| Education | 22 | 892 | 9,973 | 10,887 |
| Other retail | 2,147 | 4,076 | 516 | 6,739 |
| Total retail loans | 17,882 | 14,796 | 31,526 | 64,204 |
| Total | \$77,915 | \$19,192 | \$33,682 | \$130,789 |

⁽¹⁾ Loans held for sale are included in One Year or Less Category.

March 31, 2020 Pillar 3 Regulatory Disclosures

Table 12 below presents a summary of our credit commitments and letters of credit by remaining maturity.

| Table 12 | | | | | |
|--|----------------------|--------------------------|----------|--|--|
| | As of March 31, 2020 | | | | |
| (in millions) | One Year or Less | Greater than One Year | Total | | |
| Credit commitments | | | | | |
| Commercial | \$8,069 | \$19,741 | \$27,810 | | |
| Commercial real estate | 963 | 6,701 | 7,664 | | |
| Leases | 92 | 155 | 247 | | |
| Total commercial loans and leases | 9,124 | 26,597 | 35,721 | | |
| Residential mortgages | 1,493 | _ | 1,493 | | |
| Home equity | 1 | 16,145 | 16,146 | | |
| Automobile | _ | _ | _ | | |
| Education | 124 | _ | 124 | | |
| Other retail | 11,194 | 149 | 11,343 | | |
| Total retail loans | 12,812 | 16,294 | 29,106 | | |
| Total credit commitments | 21,936 | 42,891 | 64,827 | | |
| Letters of credit | 864 | 1,200 | 2,064 | | |
| Total credit commitments and letters of credit | \$22,800 | \$44,091 | \$66,891 | | |

Please refer to Note 2 in our Form 10-Q for the period ended March 31, 2020 for a summary of securities by contractual maturity and "Schedule HC-R - Part II Risk-Weighted Assets" in our March 31, 2020 FR Y-9C for a summary of OTC derivative notional amounts by remaining maturity.

Counterparty Credit Risk-Related Disclosures

Counterparty exposure arises primarily from the OTC derivative transactions in our customer and institutional derivative portfolios. The amount of this exposure depends on the value of underlying market factors (e.g., interest and foreign exchange rates), which can be volatile and uncertain in nature. Counterparty exposure also arises (to a lesser extent) from our securities lending and borrowing activities, which includes entering into repurchase agreements.

The customer derivative portfolio consists of interest rate swap agreements and option contracts transacted to meet the financing needs of our customers. Swap agreements and interest rate options agreements are transacted to effectively minimize our market risk associated with the customer derivative products. The customer derivative portfolio also includes foreign exchange forward agreements and option contracts entered into on behalf of customers for the purpose of hedging exposure related to cash orders, loans, and deposits denominated in foreign currencies. Customer trades are primarily unsecured and are not subject to daily margin or posting of financial collateral. We commonly execute these trades concurrently with new loan transactions, with any business collateral received from a counterparty applied to both the derivative and loan. Accordingly, the underwriting process for establishing customer derivative credit limits is equivalent to the process used for corporate loan exposure. We establish these limits based on potential future exposure using stochastic models developed by F.I.S., a third party risk management software solution provider. The models utilize Monte Carlo methods consistent with industry practice and are subject to risk governance for model risk management and validation. We manage the credit risk of our customer derivative positions by diversifying our positions among various counterparties and in certain cases, transferring the counterparty credit risk related to interest rate swaps to third parties using risk participation agreements. When measuring the fair value of our customer derivative portfolio for GAAP financial reporting purposes, we include a CVA that reflects the credit quality of the swap counterparty, as well as factors in our own credit quality. For more information on our valuation methodologies, please refer to Note 19 in our 2019 Form 10-K.

Residential loan derivatives include loan commitments that allow residential mortgage customers to lock in the interest rate on a residential mortgage while the loan undergoes the underwriting process. We use forward sales contracts to protect the value of residential mortgage loans and loan commitments that are being underwritten for

March 31, 2020 Pillar 3 Regulatory Disclosures

future sale to investors in the secondary market. We also hedge the fair market value movements of certain mortgage servicing rights using various interest rate derivative contracts.

The institutional derivative portfolio primarily consists of interest rate swap agreements used to hedge the interest rate risk associated with our loans and financing liabilities (e.g., borrowed funds, deposits, etc.). Institutional swaps and swaps executed to mitigate the market risk associated with our customer derivative products and residential loan derivatives include bilateral trades with dealers and cleared trades with central counterparties. These trades must comply with daily margin requirements where we post financial collateral based on pre-defined "posting thresholds". Posting thresholds represent the amount of exposure that counterparties are willing to accept on an unsecured basis. We post collateral only when the market value of any outstanding swaps exceeds that threshold. Changes in our own creditworthiness do not generally have an impact on the amount of collateral posted given zero thresholds have become the market convention. Bilateral trades with dealers are subject to counterparty credit limits that cover replacement costs and potential changes in market value based on a ten day close out period. Cleared trades with central counterparties are subject to counterparty credit limits for initial margin requirements where we post collateral, but where the collateral is operationally commingled with initial margin owed to other clients of the clearing broker.

Our repurchase agreements are typically short-term transactions (i.e., overnight), but they may be extended to longer terms-to-maturity (not to exceed 270 days). We fully collateralize such transactions and account for them as secured borrowings in our financial statements. We establish counterparty credit limits to monitor our overcollateralized position, which represents the difference between the market value of the collateral pledged and the amount we borrow. When permitted by GAAP, we offset short-term receivables with short-term payables associated with our reverse repurchase agreements.

On a daily basis we monitor counterparty credit exposures for counterparties with an established CSA to ensure appropriately sized collateral levels to cover risk. We manage collateral received from third parties and held pursuant to the terms of the governing CSA agreement for the counterparty, in either a tri-party custodial, segregated or an omnibus account. The collateral requirements are negotiated on each established CSA and primarily include cash in the form of U.S. Dollars.

Please refer to Note 9 in our Form 10-Q for the period ended March 31, 2020 for fair value of our derivative transactions on both a gross and net basis. The net basis presented represents the impact of enforceable master netting agreements as well as collateral paid and received.

Please refer to Note 2 in our Form 10-Q for the period ended March 31, 2020 for information on our repurchase agreements and Note 13 in our Form 10-Q for the period ended March 31, 2020 for the fair value of our repurchase agreements.

March 31, 2020 Pillar 3 Regulatory Disclosures

Credit Risk Mitigation

Our credit risk mitigation that is recognized for the purposes of reducing capital requirements is limited to implicit and explicit credit guarantees provided by the U.S. Government. We do not use collateral as a source of credit risk mitigation for the purposes of reducing capital requirements. Table 13 below presents our total exposure covered by guarantees and the risk-weighted amounts associated with each exposure.

| Table 13 | | | | | |
|---|-------------------------------|----------------|------|--|--|
| (dollars in millions) | As of A | March 31, 2020 | | | |
| Guarantor | Guaranteed Exposure Amount | RWA | RW % | | |
| FNMA & FHLMC | \$12,836 | \$2,567 | 20% | | |
| Federal Housing Administration (FHA) | 480 | 95 | 20 | | |
| Small Business Administration (SBA) | 113 | 23 | 20 | | |
| Federal Family Education Loan Program (FFELP) where 97% of exposure is guaranteed | 38 | 8 | 20 | | |
| Federal Family Education Loan Program (FFELP) where 98% of exposure is guaranteed | 14 | 3 | 20 | | |
| Veteran Affairs (VA) | 41 | 8 | 20 | | |
| United States Department of Agriculture (USDA) | 5 | 1 | 20 | | |
| Total implicit guarantees | \$13,527 | \$2,705 | 20% | | |
| US Treasury & GNMA securities | \$11,331 | \$- | 0% | | |
| Export/Import | 9 | _ | 0 | | |
| Total explicit guarantees | \$11,340 | \$- | 0% | | |

SECURITIZATION

A securitization exposure is a transaction in which the credit risk of the underlying exposure transfers to third parties and is separated into two or more tranches. The performance of a securitization depends upon the performance of the underlying exposures or reference assets, all or substantially all of which are financial exposures. We participate in the securitization market as an investor and a lender in traditional securitization exposures, however not as an originator or sponsor. We invest in securitization exposures of third party issued non-agency MBS. We also may act as a securitization lender by entering into asset-backed securitization loans with third party sponsored special purpose entities that are designed to meet client needs for long-term financing of assets or working capital. We calculate the regulatory capital requirement for securitization exposure in accordance with the U.S. Basel III Standardized approach. RWA for securitization exposures is determined using SSFA. The SSFA framework considers our seniority in the securitization structure and risk factors inherent in the underlying assets.

We do not apply credit risk mitigation to our securitized exposures and do not have exposure to securitization guarantors. We do not have synthetic securitization exposure and all securitization exposures are held on our balance sheet.

Risk Management

We manage the risks related to securitization positions in accordance with the investment, credit, and interest rate risk management policies. Please refer to "Management's Discussion and Analysis of Financial Condition and Results of Operations - Risk Governance" in our 2019 Form 10-K for more information on our credit risk and interest rate risk (i.e., non-trading risk) governance. For each securitization position, we perform due diligence on the credit worthiness of each position prior to entering into that position. Our due diligence procedures provide a comprehensive understanding of the features that would materially affect the performance of a securitization, and are commensurate with the complexity of each securitization position held.

March 31, 2020 Pillar 3 Regulatory Disclosures

Table 14 below presents our exposures receiving securitization capital treatment by collateral type and capital treatment method.

| | Table 1 | 4 | | | | |
|-------------------------------------|----------|------------------|---------------|---------|----------|-------|
| | | | As of March 3 | 1, 2020 | | |
| | SSFA | SSFA 1250% Total | | | | |
| (in millions) | Exposure | RWA | Exposure | RWA | Exposure | RWA |
| Asset-backed securitization lending | \$2,575 | \$521 | \$- | \$- | \$2,575 | \$521 |
| Private label residential MBS | 612 | 123 | _ | _ | 612 | 123 |
| Total securitization exposure | \$3,187 | \$644 | \$- | \$- | \$3,187 | \$644 |

Table 15 below presents our exposures receiving securitization capital treatment by capital treatment method and risk weighting.

| | Table 1 | 5 | | | | |
|------------------------------------|----------------------|-------|----------|-----|----------|-------|
| | As of March 31, 2020 | | | | | |
| | SSFA | | 1250% | 5 | Total | |
| (in millions) | Exposure | RWA | Exposure | RWA | Exposure | RWA |
| Securitizations by risk weight: | | | | | | |
| = 0% to <= 20% | \$2,918 | \$584 | \$- | \$— | \$2,918 | \$584 |
| > 20% to <= 50% | 269 | 60 | _ | _ | 269 | 60 |
| > 50% to <= 100% | _ | _ | _ | _ | _ | _ |
| > 100% to <= 1250% | _ | _ | _ | _ | _ | _ |
| Total securitizations | \$3,187 | \$644 | \$- | \$- | \$3,187 | \$644 |
| Re-securitizations by risk weight: | | | | | | |
| = 0% to <= 20% | \$— | \$— | \$- | \$— | \$— | \$- |
| Total re-securitizations | \$- | \$- | \$- | \$- | \$- | \$- |
| Total securitization exposure | \$3,187 | \$644 | \$- | \$- | \$3,187 | \$644 |

Accounting Policies

Our accounting policy for investments in securitized assets (i.e., "investments in debt securities") is presented in Note 3 in our 2019 Form 10-K.

EQUITIES (NON-TRADING)

We hold equity securities to fulfill requirements of membership and participation in U.S. banking and payments systems. Our bank holds stock in the FRB and the FHLB. Our equity holdings are limited to immaterial amounts of stock. We also invest in fund and non-fund equities. The non-fund equities use the simple risk-weight approach and primarily consist of investments in community projects in conjunction with our commitment to the communities in which we operate. These investments also fulfill specific requirements imposed by the CRA as implemented by the U.S. regulatory agencies. In addition to CRA investments, we invest in renewable wind energy projects, providing benefits from returns generated by government incentives plus other tax attributes that come with ownership. We also have invested amounts in fund-related equity investments, consisting of money market mutual fund investments and separate account bank owned life insurance. The underlying assets of separate account bank owned life insurance consist primarily of treasuries, mortgaged-backed securities, and bonds. The fund-related equity investments use the full look-through approach to determine risk weight.

March 31, 2020 Pillar 3 Regulatory Disclosures

Our accounting policy for equity securities (i.e., "other investment securities") is presented in Note 3 in our 2019 Form 10-K. We present methodologies for measuring the fair value of equity securities in Note 19 in our 2019 Form 10-K. The carrying value of our CRA investments are included in the other assets line in "Financial Statements - Consolidated Balance Sheets" in our Form 10-Q for the period ended March 31, 2020. Separate account bank-owned life insurance is included in the bank-owned life insurance line within the "Financial Statements - Consolidated Balance Sheets" in our Form 10-Q for the period ended March 31, 2020. Table 16 below presents our equity exposures and the risk-weighted amounts associated with each exposure.

| Table | e 16 | | |
|--|----------------------|---------|------|
| | As of March 31, 2020 | | |
| (dollars in millions) | Exposure | RWA | RW % |
| Federal Reserve stock | \$577 | \$- | 0% |
| FHLB stock | 343 | 69 | 20 |
| Investments in Non-Fund Equities: | | | |
| CRA | 1,493 | 1,493 | 100 |
| Windfarm | 423 | 423 | 100 |
| Other Non-Fund Equities | 8 | 8 | 100 |
| Investment in Fund Equities: | | | |
| Separate account bank owned life insurance | 260 | 102 | 39 |
| Money market mutual fund investments | 46 | 9 | 20 |
| Total | \$3,150 | \$2,104 | |

MARKET RISK

Non-Trading Risk

We are exposed to market risk as a result of non-trading banking activities. This market risk is substantially composed of interest rate risk, as we have no commodity risk and de minimis direct currency and equity risk. We also have market risk related to capital markets loan originations, as well as the valuation of our MSRs. Please refer to "Management's Discussion and Analysis of Financial Condition and Results of Operations - Market Risk - Non-Trading Risk" in our Form 10-Q for the period ended March 31, 2020 for more information on our exposure to interest rate risk. Please refer to Note 9 in our Form 10-Q for the period ended March 31, 2020 for more information on our hedging policies and our processes for monitoring hedge effectiveness.

Trading Risk

We face market risk price volatility across a select range of interest rates, foreign exchange rates, and credit spreads through our client facilitation activities covering interest rate derivatives, foreign exchange products, and secondary loans. While we do not always meet the applicable reporting threshold of the Market Risk Rule, we nevertheless continually adhere to the Market Risk Rule covering our trading activities.

As of March 31, 2020, our market risk RWA was \$774 million, reflecting general market rate/price risk and specific risk. We do not model our specific risk through the VaR based process and thus a specific risk add-on is calculated under a standardized measurement method. We do not calculate incremental risk or comprehensive risk, as we take a standardized specific risk add-on, and we do not participate in correlation trading related activities.

For further discussion related to market risk governance, risk measurements, VaR methodology and validation, and regulatory capital, please refer to "Management's Discussion and Analysis of Financial Condition and Results of Operations - Risk Governance" in our 2019 Form 10-K and "Management's Discussion and Analysis of Financial Condition and Results of Operations - Market Risk" in our Form 10-Q for the period ended March 31, 2020.

March 31, 2020 Pillar 3 Regulatory Disclosures

APPENDIX 1 - CITIZENS FINANCIAL GROUP, INC. PILLAR 3 REGULATORY DISCLOSURES MATRIX

The disclosures required by the U.S. Basel III Standardized rule⁽¹⁾ are listed below. Most of these disclosures have been included in other financial reporting documents, and some in this report. This matrix provides a reference to the location of each required disclosure.

⁽¹⁾ Code of Federal Regulations, Part 217 - Capital Adequacy of Bank Holding Companies, Savings and Loan Holding Companies, and State Member Banks (Regulation Q).

| Disclosure Requirement | Description | Pillar 3 reference | 1Q20 10-Q | 2019 10-K |
|--------------------------------|--|-----------------------|--|--|
| 1. Scope of application | Name of the top corporate entity | pg. 4 | MD&A - Introduction | |
| | Descriptions of differences in basis for consolidating entities | pg. 4 | Note 1 - Basis of Presentation | Note 1 - Basis of Presentation |
| | Restrictions on transfers of funds or total capital within the group | pg. 4 | | |
| | Aggregate amount of surplus capital of insurance subsidiaries | N/A | | |
| | Aggregate amount of total capital that is less than minimum capital | N/A | | |
| 2. Capital structure | Terms and conditions of capital instruments | pg. 6 | | |
| | Capital composition | pg. 7 | | |
| 3. Capital adequacy | Capital adequacy assessment process | pg. 8 | MD&A - Capital and Regulatory Matters | MD&A - Capital and Regulatory Matters |
| | Capital ratios | pg. 9 | MD&A - Capital and Regulatory Matters | MD&A - Capital and Regulatory Matters |
| | Risk-weighted assets by exposure type | pg. 10 | | |
| | Market risk-weighted assets | pg. 10 | | |
| 4. Capital conservation buffer | Capital conservation buffer | pg. 10 | MD&A - Capital and Regulatory Matters | MD&A - Capital and Regulatory Matters |
| | Calculated eligible retained income | pg. 10 | | |
| | Limitations of distributions and discretionary bonus payments | pg. 10 | | |
| 5. Credit risk | Credit risk exposures | pg. 11 | | |
| | Policies and practices | pg. 5 | Note 4 - Allowance for Credit Losses, Nonaccruing Loans and Leases, and Concentrations of Credit Risk | MD&A - Risk Governance |
| | Loans and related commitments | pg. 11 | Note 3 - Loans and Leases & Note 12 - Commitments and Contingencies | Note 4 - Loans and Leases & Note 18 - Commitments and Contingencies |
| | Debt securities | pg. 11 | Note 2 - Securities | Note 3 - Securities |
| | OTC derivatives | pg. 11 | Note 9 - Derivatives & Note 13 - Fair Value Measurements | Note 13 - Derivatives |

March 31, 2020 Pillar 3 Regulatory Disclosures

| Disclosure Requirement | Description | Pillar 3 reference | 1Q20 10-Q | 2019 10-K |
|---|--|-----------------------|--|---|
| | Geographic distribution of exposures | pg. 12 | | |
| | Allowance disaggregated on the basis of impairment methodology | pg. 12 | | |
| | Charge-offs during the period | pg. 12 | Note 4 - Allowance for Credit Losses, Nonaccruing Loans and Leases, and Concentrations of Credit Risk | Note 5 - Allowance for Credit Losses, Nonperforming Assets, and Concentrations of Credit Risk |
| | Impaired loans by industry or counterparty | pg. 13 | Note 4 - Allowance for Credit Losses, Nonaccruing Loans and Leases, and Concentrations of Credit Risk | Note 5 - Allowance for Credit Losses, Nonperforming Assets, and Concentrations of Credit Risk |
| | Past due loans by product | pg. 13 | Note 4 - Allowance for Credit Losses, Nonaccruing Loans and Leases, and Concentrations of Credit Risk | Note 5 - Allowance for Credit Losses, Nonperforming Assets, and Concentrations of Credit Risk |
| | Impaired loans by geography | pg. 13 | | |
| | Reconciliation of changes in allowance | pg. 12 | Note 4 - Allowance for Credit Losses, Nonaccruing Loans and Leases, and Concentrations of Credit Risk | Note 5 - Allowance for Credit Losses, Nonperforming Assets, and Concentrations of Credit Risk |
| | Remaining maturity of loans and loans held for sale | pg. 14 | | |
| | Remaining maturity of credit commitments and letters of credit | pg. 15 | | |
| 6. Counterparty credit risk-related exposures | Policies and practices | pg. 15 | Note 9 - Derivatives | Note 13 - Derivatives |
| | Counterparty risk exposure | pg. 15 | Note 2 - Securities, Note 9 - Derivatives & Note 13 - Fair Value Measurements | Note 19 - Fair Value Measurements |
| | Credit derivatives purchased and sold | N/A | | |
| 7. Credit risk mitigation | Policies and processes | pg. 17 | | |

March 31, 2020 Pillar 3 Regulatory Disclosures

| Disclosure Requirement | Description | Pillar 3 reference | 1Q20 10-Q | 2019 10-K |
|---|---|-----------------------|---|-----------------------|
| | Exposures covered by eligible financial collateral | N/A | | |
| | Exposures covered by guarantees/credit derivatives and related risk-weighted assets | pg. 17 | | |
| 8. Securitization | Policies and practices | pg. 17 | | |
| | SPEs and affiliated entities | N/A | | |
| | Accounting policies for securitization activities | pg. 18 | | |
| | Exposures securitized by the bank and resecuritizations | N/A | | |
| | Securitization exposures by collateral type | pg. 18 | | |
| | Securitization exposures by risk weight | pg. 18 | | |
| 9. Equities not subject to the market risk rule | Policies and practices | pg. 18 | Note 7 - Variable Interest Entities | |
| | Amortized cost and fair value by type/nature and public versus nonpublic | pg. 19 | Note 13 - Fair Value Measurements | |
| | Realized and unrealized gains (losses) | N/A | | |
| | Capital requirements | pg. 18 | | |
| 10. Interest rate risk for non-trading activities | Nature, assumptions and frequency of measurement | pg. 19 | MD&A - Market Risk | MD&A - Market Risk |
| | Earnings sensitivity to rate movements | pg. 19 | MD&A - Market Risk | MD&A - Market Risk |

March 31, 2020 Pillar 3 Regulatory Disclosures

APPENDIX 2 - FORWARD-LOOKING STATEMENTS

This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements regarding potential future share repurchases and future dividends as well as the potential effects of the COVID-19 pandemic on our business, operations, financial performance and prospects, are forward-looking statements. Also, any statement that does not describe historical or current facts is a forward-looking statement. These statements often include the words "believes," "expects," "anticipates," "estimates," "intends," "plans," "goals," "targets," "initiatives," "potentially," "probably," "projects," "outlook" or similar expressions or future conditional verbs such as "may," "will," "should," and "could."

Forward-looking statements are based upon the current beliefs and expectations of management, and on information currently available to management. Our statements speak as of the date hereof, and we do not assume any obligation to update these statements or to update the reasons why actual results could differ from those contained in such statements in light of new information or future events. We caution you, therefore, against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. While there is no assurance that any list of risks and uncertainties or risk factors is complete, important factors that could cause actual results to differ materially from those in the forward-looking statements include the following, without limitation:

- Negative economic and political conditions that adversely affect the general economy, housing prices, the job market, consumer confidence and spending habits which may affect, among other things, the level of nonperforming assets, charge-offs and provision expense;
- The rate of growth in the economy and employment levels, as well as general business and economic conditions, and changes in the competitive environment;
- Our ability to implement our business strategy, including the cost savings and efficiency components, and achieve our financial performance goals;
- The COVID-19 pandemic and its effects on the economic and business environments in which we operate;
- Our ability to meet heightened supervisory requirements and expectations;
- Liabilities and business restrictions resulting from litigation and regulatory investigations;
- Our capital and liquidity requirements (including under regulatory capital standards, such as the U.S. Basel III capital rules) and our ability to generate capital internally or raise capital on favorable terms;
- The effect of changes in interest rates on our net interest income, net interest margin and our mortgage originations, mortgage servicing rights and mortgages held for sale;
- Changes in interest rates and market liquidity, as well as the magnitude of such changes, which may reduce interest margins, impact funding sources and affect the ability to originate and distribute financial products in the primary and secondary markets;
- The effect of changes in the level of checking or savings account deposits on our funding costs and net interest margin;
- Financial services reform and other current, pending or future legislation or regulation that could have a negative
 effect on our revenue and businesses;
- A failure in or breach of our operational or security systems or infrastructure, or those of our third party vendors or other service providers, including as a result of cyber-attacks; and
- Management's ability to identify and manage these and other risks.

In addition to the above factors, we also caution that the actual amounts and timing of any future common stock dividends or share repurchases will be subject to various factors, including our capital position, financial performance, capital impacts of strategic initiatives, market conditions and regulatory and accounting considerations, as well as any other factors that our Board of Directors deems relevant in making such a determination. Therefore, there can be no assurance that we will repurchase shares from or pay any dividends to holders of our common stock, or as to the amount of any such repurchases or dividends. Further, statements about the effects of the COVID-19 pandemic on our business, operations, financial performance and prospects may constitute what is reflected in those forward-looking statements due to factors and future developments that are uncertain, unpredictable and in many cases beyond our control, including the scope and duration of the pandemic, actions taken by governmental authorities in response to the pandemic, and the direct and indirect impact of the pandemic on our customers, third parties and us.

March 31, 2020 Pillar 3 Regulatory Disclosures

More information about factors that could cause actual results to differ materially from those described in the forward-looking statements can be found in the "Risk Factors" section in Part II, Item 1A of our Form 10-Q for the period ended March 31, 2020 and Part I, Item 1A. of our Annual Report on Form 10-K for the year ended December 31, 2019.